Cancer-associated_cachexia

GDF15: from biomarker to target in cancer cachexia.

Most patients with advanced cancer suffer from cachexia, a complex metabolic disorder characterized by unintentional body weight loss that diminishes their quality of life and reduces the effectiveness of therapies. Currently, effective treatments for cachexia remain elusive. Growth differentiation factor...

🗓️ 2025-07-09
📰 Publication: Trends In Cancer
Read MoreGDF15: from biomarker to target in cancer cachexia.

Scutellarein attenuates cancer cachexia-induced muscle atrophy via targeted inhibition of the JAK/STAT pathway.

Cancer cachexia is a multifaceted metabolic syndrome characterized by severe loss of skeletal muscle and adipose tissue, diminishing both quality of life and survival in cancer patients. Despite its prevalence, effective treatments for cancer cachexia remain limited. The JAK/STAT signaling...

🗓️ 2025-07-03
📰 Publication: Journal Of Advanced Research
Read MoreScutellarein attenuates cancer cachexia-induced muscle atrophy via targeted inhibition of the JAK/STAT pathway.

Pancreatic Cancer-Derived Extracellular Vesicles Enriched with miR-223-5p Promote Skeletal Muscle Wasting Associated with Cachexia.

Pancreatic ductal adenocarcinoma (PDAC) with cachexia-related muscle wasting as the main manifestation is associated with poor overall survival. Extracellular vesicles (EVs) are key mediators of inter-organ communication. Here, EVs and EV-microRNAs (miRNAs) are identified as mediate PDAC-skeletal muscle communication. EVs...

🗓️ 2025-07-02
Read MorePancreatic Cancer-Derived Extracellular Vesicles Enriched with miR-223-5p Promote Skeletal Muscle Wasting Associated with Cachexia.

Effect of Cancer Cachexia on the Efficacy and Treatment Delivery of Chemotherapy in Older Patients With Advanced Small Cell Lung Cancer.

Cachexia is a syndrome in patients with cancer that reduces life quality and prognosis, characterized by severe weight loss, muscle atrophy, and anorexia. How cachexia adversely affects older patients with small cell lung cancer (SCLC) remains uncertain. This study aimed...

🗓️ 2025-06-01
📰 Publication: Thoracic Cancer
Read MoreEffect of Cancer Cachexia on the Efficacy and Treatment Delivery of Chemotherapy in Older Patients With Advanced Small Cell Lung Cancer.

Exercise and Nutrition Therapy in a Patient With Glottic Cancer Cachexia Undergoing Chemoradiotherapy: A Case Report.

Cancer cachexia is a common complication in patients undergoing chemoradiotherapy (CRT) for head and neck cancer (HNC), leading to skeletal muscle loss, decreased physical function, and poor prognosis. Cachexia is frequently observed in patients with HNC, yet evidence supporting effective...

🗓️ 2025-05-20
Read MoreExercise and Nutrition Therapy in a Patient With Glottic Cancer Cachexia Undergoing Chemoradiotherapy: A Case Report.

Desensitizing Effect of Intra-Tumoral GDF-15 on Immunotherapy in Patients With Advanced Non-Small Cell Lung Cancer.

Serum growth/differentiation factor 15 (GDF-15) suppresses anti-tumor immunity and predicts prognosis in several malignancies. Elevated GDF-15 levels are linked to cancer cachexia, characterized by weight loss and systemic inflammation, adversely affecting patient outcomes and therapy response. However, serum GDF-15 is...

🗓️ 2025-05-01
📰 Publication: Thoracic Cancer
Read MoreDesensitizing Effect of Intra-Tumoral GDF-15 on Immunotherapy in Patients With Advanced Non-Small Cell Lung Cancer.

The potential of TAOK1 as a new therapeutic target for the treatment of cancer cachexia-associated muscle atrophy.

Cancer cachexia, a multifactorial metabolic syndrome impacts 50-80% cancer patients, is mainly characterized by skeletal muscle atrophy. In this study, we demonstrated that the thousand-and-one amino acid kinase 1 (TAOK1) was activated in both C2C12 myotubes treated with simulated cancer...

🗓️ 2025-05-06
📰 Publication: Pharmacological Research
Read MoreThe potential of TAOK1 as a new therapeutic target for the treatment of cancer cachexia-associated muscle atrophy.

Stool Microbiome Features and Weight Change Response to Treatment for cancer cachexia.

Cancer cachexia is characterised by significant weight loss and muscle wasting that adversely affects patient outcomes. Nutritional interventions in cancer cachexia leads to improved outcomes, including improved weight change. However, there are wide variations in weight response to dietary interventions....

🗓️ 2025-06-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreStool Microbiome Features and Weight Change Response to Treatment for cancer cachexia.

Hepatic gluconeogenesis and PDK3 upregulation drive cancer cachexia in flies and mice.

Cachexia, a severe wasting syndrome characterized by tumour-induced metabolic dysregulation, is a leading cause of death in people with cancer, yet its underlying mechanisms remain poorly understood. Here we show that a longitudinal full-body single-nuclei-resolution transcriptome analysis in a Drosophila...

🗓️ 2025-04-16
Read MoreHepatic gluconeogenesis and PDK3 upregulation drive cancer cachexia in flies and mice.

Myocellular adaptations to short-term weighted wheel-running exercise are largely conserved during C26-tumour induction in male and female mice.

This study investigated whether performing a translatable murine model of concurrent training after tumour induction affects adaptations in juvenile male and female tumour-bearing mice. Male and female Balb/c mice were injected bilaterally with colon-26 adenocarcinoma (C26) cells or PBS at...

🗓️ 2025-04-24
📰 Publication: Experimental Physiology
Read MoreMyocellular adaptations to short-term weighted wheel-running exercise are largely conserved during C26-tumour induction in male and female mice.

INFLAMMATION IN CANCER CACHEXIA: STILL THE CENTRAL TENET OR JUST ANOTHER PLAYER?

Cancer cachexia, a multifactorial syndrome characterised by body weight loss, muscle and adipose tissue wasting, affects cancer patients. Over time, the definition of cachexia has been modified, including inflammation as one of the main causal factors. Evidences have suggested that...

🗓️ 2025-04-18
📰 Publication: American Journal Of Physiology-Cell Physiology
Read MoreINFLAMMATION IN CANCER CACHEXIA: STILL THE CENTRAL TENET OR JUST ANOTHER PLAYER?

Blood-Brain Barrier-Penetrating Nanocarriers Enable Microglial-Specific Drug Delivery in Hypothalamic Neuroinflammation.

Hypothalamic inflammation plays a pivotal role in appetite dysregulation across various pathological conditions, including cancer cachexia. However, delivering anti-inflammatory agents to microglia, key mediators of hypothalamic inflammation, remains challenging due to the unsurmountable blood-brain barrier (BBB). To overcome this challenge,...

🗓️ 2025-04-03
📰 Publication: Advanced Healthcare Materials
Read MoreBlood-Brain Barrier-Penetrating Nanocarriers Enable Microglial-Specific Drug Delivery in Hypothalamic Neuroinflammation.

Nuciferine Attenuates Cancer Cachexia-Induced Muscle Wasting in Mice via HSP90AA1.

Around 80% of patients with advanced cancer have cancer cachexia (CC), a serious complication for which there are currently no FDA-approved treatments. Nuciferine (NF) is the main active ingredient of lotus leaf, which has anti-inflammatory, anti-tumour and other effects. The...

🗓️ 2025-04-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreNuciferine Attenuates Cancer Cachexia-Induced Muscle Wasting in Mice via HSP90AA1.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!